<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><description>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 08 Apr 2021 10:14:13 +0800</pubDate><image><url>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</url><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>NSCLC术后辅助治疗！奥希替尼新适应症获批</title><link>https://mp.weixin.qq.com/s/MA5-GP-bgO9BYB_7Q27Ztw</link><description></description><content:encoded><![CDATA[NSCLC术后辅助治疗！奥希替尼新适应症获批]]></content:encoded><pubDate>Thu, 08 Apr 2021 09:31:00 +0800</pubDate></item><item><title>特瑞普利单抗第3项适应症获批！治疗尿路上皮癌</title><link>https://mp.weixin.qq.com/s/RZe7xABa2E8REctuH6ir-Q</link><description></description><content:encoded><![CDATA[特瑞普利单抗第3项适应症获批！治疗尿路上皮癌]]></content:encoded><pubDate>Thu, 08 Apr 2021 09:31:00 +0800</pubDate></item><item><title>武田「醋酸艾替班特注射液」在华获批上市</title><link>https://mp.weixin.qq.com/s/BR7EQbxNWTJxpAuLY_jnIQ</link><description></description><content:encoded><![CDATA[武田「醋酸艾替班特注射液」在华获批上市]]></content:encoded><pubDate>Thu, 08 Apr 2021 09:31:00 +0800</pubDate></item><item><title>国内首个申报上市PI3K抑制剂拟纳入优先审评</title><link>https://mp.weixin.qq.com/s/8iAL7qBI4OSLWIVXuE_o6w</link><description></description><content:encoded><![CDATA[国内首个申报上市PI3K抑制剂拟纳入优先审评]]></content:encoded><pubDate>Wed, 07 Apr 2021 17:37:03 +0800</pubDate></item><item><title>首个GLP-1/FGF21双重激动剂同时获批2项临床</title><link>https://mp.weixin.qq.com/s/ZlqoQOw7QLwR-4-AdZzrFg</link><description></description><content:encoded><![CDATA[首个GLP-1/FGF21双重激动剂同时获批2项临床]]></content:encoded><pubDate>Wed, 07 Apr 2021 17:37:03 +0800</pubDate></item><item><title>君实生物CTLA-4 单抗临床申请获受理</title><link>https://mp.weixin.qq.com/s/BQoCo6TEKL7uTkdTsuK5HA</link><description></description><content:encoded><![CDATA[君实生物CTLA-4 单抗临床申请获受理]]></content:encoded><pubDate>Wed, 07 Apr 2021 17:37:03 +0800</pubDate></item><item><title>全球首个BTK-PROTAC获批临床</title><link>https://mp.weixin.qq.com/s/X6mDycMtjo2kNXxphdwxqA</link><description></description><content:encoded><![CDATA[全球首个BTK-PROTAC获批临床]]></content:encoded><pubDate>Tue, 06 Apr 2021 18:24:56 +0800</pubDate></item><item><title>2021年3月 | 失败临床研究TOP10</title><link>https://mp.weixin.qq.com/s/5RasJHathbj9Y8RE9ZDGdw</link><description></description><content:encoded><![CDATA[2021年3月 | 失败临床研究TOP10]]></content:encoded><pubDate>Tue, 06 Apr 2021 18:24:56 +0800</pubDate></item><item><title>近十年来首个非兴奋剂类ADHD药物获FDA批准上市</title><link>https://mp.weixin.qq.com/s/hRWQtuSfMi-6bl1cdWkTsg</link><description></description><content:encoded><![CDATA[近十年来首个非兴奋剂类ADHD药物获FDA批准上市]]></content:encoded><pubDate>Tue, 06 Apr 2021 18:24:56 +0800</pubDate></item><item><title>贝达药业KRAS G12C抑制剂获批临床</title><link>https://mp.weixin.qq.com/s/IVSuwX5w8DtpjeiioYugtA</link><description></description><content:encoded><![CDATA[贝达药业KRAS G12C抑制剂获批临床]]></content:encoded><pubDate>Tue, 06 Apr 2021 18:24:56 +0800</pubDate></item><item><title>强生/传奇生物BCMA CAR-T完成美国BLA滚动申请</title><link>https://mp.weixin.qq.com/s/WanAYGzgj3lMZOYFcqxFrQ</link><description></description><content:encoded><![CDATA[强生/传奇生物BCMA CAR-T完成美国BLA滚动申请]]></content:encoded><pubDate>Tue, 06 Apr 2021 18:24:56 +0800</pubDate></item><item><title>上市还有希望吗？渤健阿尔茨海默症单抗aducanumab再遭FDA委员会抨击</title><link>https://mp.weixin.qq.com/s/NByZLuz16MOpj_ZB1S8bCg</link><description></description><content:encoded><![CDATA[上市还有希望吗？渤健阿尔茨海默症单抗aducanumab再遭FDA委员会抨击]]></content:encoded><pubDate>Fri, 02 Apr 2021 18:30:20 +0800</pubDate></item><item><title>京津冀晋11品种集采4月15日开标，中标规则对标国采</title><link>https://mp.weixin.qq.com/s/vRavNIscoek4VuQqq_bwZg</link><description></description><content:encoded><![CDATA[京津冀晋11品种集采4月15日开标，中标规则对标国采]]></content:encoded><pubDate>Fri, 02 Apr 2021 18:30:20 +0800</pubDate></item><item><title>吉利德CAR-T疗法向FDA递交sBLA申请</title><link>https://mp.weixin.qq.com/s/pCYNmXCYeIYzaYB0cWE-sg</link><description></description><content:encoded><![CDATA[吉利德CAR-T疗法向FDA递交sBLA申请]]></content:encoded><pubDate>Fri, 02 Apr 2021 18:30:20 +0800</pubDate></item><item><title>2021年3月FDA批准的5款新药</title><link>https://mp.weixin.qq.com/s/4wQS6VNYSPeZA_LhSxsaxw</link><description></description><content:encoded><![CDATA[2021年3月FDA批准的5款新药]]></content:encoded><pubDate>Thu, 01 Apr 2021 17:22:53 +0800</pubDate></item><item><title>符合第五批集采条件品种注射用更昔洛韦，普利制药再下一城获意大利批准</title><link>https://mp.weixin.qq.com/s/gAdy55nLVNmW8oxpUVc-wQ</link><description></description><content:encoded><![CDATA[符合第五批集采条件品种注射用更昔洛韦，普利制药再下一城获意大利批准]]></content:encoded><pubDate>Thu, 01 Apr 2021 17:22:53 +0800</pubDate></item><item><title>朗来科技IRAK4抑制剂MY004临床试验申请获国家药品监督管理局受理</title><link>https://mp.weixin.qq.com/s/g3JITGpSxjKKhQplOZTxCQ</link><description></description><content:encoded><![CDATA[朗来科技IRAK4抑制剂MY004临床试验申请获国家药品监督管理局受理]]></content:encoded><pubDate>Thu, 01 Apr 2021 17:22:53 +0800</pubDate></item><item><title>强生BCMA/CD3双抗申报临床</title><link>https://mp.weixin.qq.com/s/yMgw9vH6-06Iv5Fc441wcw</link><description></description><content:encoded><![CDATA[强生BCMA/CD3双抗申报临床]]></content:encoded><pubDate>Thu, 01 Apr 2021 17:22:53 +0800</pubDate></item><item><title>方生和与PICC再度合作，投保在研药物临床试验</title><link>https://mp.weixin.qq.com/s/pi2XwR3JeyP3Jr0fnQU9JA</link><description></description><content:encoded><![CDATA[方生和与PICC再度合作，投保在研药物临床试验]]></content:encoded><pubDate>Thu, 01 Apr 2021 17:22:53 +0800</pubDate></item><item><title>再鼎医药「瑞派替尼」国内获批上市，填补GIST四线治疗空白</title><link>https://mp.weixin.qq.com/s/YPs84lUrB7dco41syBuZtA</link><description></description><content:encoded><![CDATA[再鼎医药「瑞派替尼」国内获批上市，填补GIST四线治疗空白]]></content:encoded><pubDate>Wed, 31 Mar 2021 17:15:24 +0800</pubDate></item></channel></rss>